Recombinant Human VEGF-C Protein Best Seller

R&D Systems, part of Bio-Techne | Catalog # 9199-VC

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Carrier Free
9199-VC-025/CF
Catalog #
Availability
Size / Price
Qty
With Carrier
9199-VC-025
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

P49767

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all VEGF-C Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human VEGF-C protein
Ala112-Arg227

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala112

Predicted Molecular Mass

13 kDa

SDS-PAGE

14-22 kDa, reducing conditions

Activity

Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671.
The ED50 for this effect is 1.5-9 ng/mL.

Scientific Data Images for Recombinant Human VEGF-C Protein

Recombinant Human VEGF-C Protein Bioactivity

Recombinant Human VEGF-C Protein Bioactivity

Recombinant Human VEGF-C (Catalog # 9199-VC) induces HMVEC human microvascular endothelial cell proliferation. The ED50 for this effect is 1.5-9 ng/mL. The ED50 for the three competitors is >30 ng/mL, which is at least more than 10-fold weaker.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 9199-VC
Formulation Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 9199-VC/CF
Formulation Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF-C

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).

References

  1. Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
  2. Joukov, V. et al. (1996) EMBO J. 15:290.
  3. Kukk, E. et al. (1996) Development 122:3829.
  4. Joukov, V. et al. (1997) EMBO J. 16:3898.
  5. Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
  6. Jeltsch, M. et al. (1997) Science 276:1423.
  7. Makinen, T. et al. (2001) Nat. Med. 7:199.
  8. Laakkonen, P. et al. (2007) Cancer Res. 67:593.
  9. Hoshida, T. et al. (2006) Cancer Res. 66:8065.
  10. Mandriota, S.J. et al. (2001) EMBO J. 20:672.
  11. Skobe, M. et al. (2001) Nat. Med. 7:192.
  12. Padera, T.P. et al. (2002) Science 296:1883.
  13. Tammela, T. et al. (2008) Nature 454:656.
  14. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.

Long Name

Vascular Endothelial Growth Factor C

Alternate Names

VEGFC

Entrez Gene IDs

7424 (Human); 22341 (Mouse)

Gene Symbol

VEGFC

UniProt

P49767 (Human)

Additional VEGF-C Products

Product Documents for Recombinant Human VEGF-C Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS 9199-VC (with carrier)
Download SDS 9199-VC/CF (carrier free)

Product Specific Notices for Recombinant Human VEGF-C Protein

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.